Skip to main content
. 2012 Apr 20;7(4):e35055. doi: 10.1371/journal.pone.0035055

Table 4. Ipsilateral/contralateral ratio of N100m.

ISSNHL patient
Control Initial 1 m
Left Right Healthy Affected Healthy Affected
I/Ca I/Cl I/Cas I/Cls I/Ca I/Cl I/Cas I/Cls I/Ca I/Cl I/Cas I/Cls I/Ca I/Cl I/Cas I/Cls I/Ca I/Cl I/Cas I/Cls I/Ca I/Cl I/Cas I/Cls
1 0.46 1.21 0.92 1.14 1.60 1.04 0.80 1.10 1.08 1.11 0.91 1.04 0.46 1.13 0.55 1.21 0.84 1.09 1.24 1.07 1.49 1.09 1.01 1.11
2 0.86 0.97 0.50 0.89 0.86 1.04 1.47 1.13 3.17 1.00 1.75 0.69 0.31 1.08 0.56 1.58 2.87 1.06 0.96 1.07 0.40 0.91 1.19 0.90
3 0.42 1.24 0.48 1.14 0.70 0.98 0.62 1.07 2.64 0.94 0.83 1.11 0.30 0.94 0.96 0.80 1.72 1.00 0.84 0.95 0.43 1.00 0.88 1.05
4 0.33 1.27 0.75 1.16 0.94 0.97 0.41 1.06 0.57 1.27 2.26 0.76 0.90 0.91 0.23 1.53 0.80 1.17 1.11 0.98 1.13 1.00 0.82 1.19
5 0.39 1.19 0.41 1.07 0.68 1.09 0.65 1.21 1.36 0.88 1.07 1.03 0.89 1.00 1.13 0.86 0.76 1.09 0.95 0.98 0.98 1.10 0.78 1.22
6 0.77 1.14 0.94 1.12 0.83 1.08 0.68 1.09 0.68 1.17 1.07 0.86 0.43 1.22 0.27 1.67 0.80 1.05 1.74 0.81 0.85 1.25 0.39 1.62
7 0.22 1.38 0.35 1.31 0.74 1.22 0.46 1.28 2.42 1.05 1.04 0.82 0.42 1.02 0.98 1.30 2.01 1.04 1.08 0.99 0.28 1.00 0.52 1.05
8 1.08 1.31 0.64 1.15 0.35 1.00 0.59 1.14 1.10 1.22 0.58 0.91 0.33 1.01 0.63 1.36 0.85 1.05 0.49 0.94 0.91 0.94 1.56 1.04
9 1.07 0.91 0.79 1.07 0.57 1.17 0.78 0.98 1.18 1.19 1.83 0.75 0.71 1.04 0.46 1.66 0.76 1.65 1.82 1.42 2.82 1.28 1.18 1.50
10 0.42 1.10 0.48 0.82 0.70 1.05 0.62 1.41 1.01 1.41 1.52 0.75 1.01 0.86 0.67 1.60 0.47 1.05 1.06 1.12 0.89 1.39 0.39 1.30
11 1.49 1.05 0.85 1.29 0.92 1.20 1.62 0.97 1.15 1.16 0.76 0.99 0.69 0.99 1.05 1.15 0.66 1.00 0.56 0.88 0.85 1.00 1.01 1.13
12 0.86 1.45 0.72 1.02 1.25 0.82 1.49 1.17 1.06 1.10 0.79 0.94 0.45 1.11 0.61 1.30 0.84 1.18 1.41 1.06 0.74 0.98 0.44 1.09
13 0.53 1.10 0.66 1.14 0.70 1.24 0.56 1.19 1.18 1.15 1.62 1.15 0.49 1.44 0.36 1.44 1.03 1.20 0.49 1.09 0.34 1.11 0.71 1.22
14 0.59 1.09 0.56 1.32 0.82 1.25 0.87 1.03 1.18 1.00 0.85 1.10 0.40 1.22 0.56 1.11 1.19 1.00 1.74 0.85 0.86 1.10 0.59 1.29
15 0.50 1.16 0.71 1.09 1.10 1.09 0.78 1.16 1.04 1.09 0.86 1.08 0.37 1.18 0.45 1.19 3.13 1.10 1.88 1.10 0.52 1.20 0.86 1.20
16 0.47 1.19 0.65 1.09 1.09 1.09 0.78 1.19 1.01 1.09 0.86 1.07 0.54 1.35 0.63 1.38 0.88 1.08 0.80 1.01 0.67 0.97 0.74 1.04
17 0.54 1.42 0.31 1.29 0.55 1.47 0.98 1.62 1.81 1.02 0.72 1.20 0.46 1.52 1.16 1.30 0.64 1.00 0.95 1.19 0.75 1.29 0.51 1.08
18 0.96 1.08 0.83 1.08 0.90 1.08 1.04 1.08 1.49 0.91 4.01 0.57 1.11 0.87 0.41 1.39 1.15 0.98 3.14 0.74 1.26 1.13 0.46 1.51
19 0.94 1.07 0.57 1.07 0.74 1.16 1.22 1.16 1.23 0.92 0.66 1.13 0.44 1.33 0.83 1.08 1.09 0.92 0.77 1.10 0.82 1.30 1.17 1.08
20 0.62 1.18 0.84 1.18 0.97 1.11 0.72 1.11 1.01 1.10 0.38 1.07 0.45 1.26 1.19 1.30 0.65 1.09 0.65 1.20 0.39 1.30 0.39 1.18
21 0.38 1.10 0.43 1.17 0.65 1.27 0.43 1.17 0.53 1.11 0.48 1.02 0.88 1.19 0.99 1.29 0.92 1.04 0.86 0.98 0.42 1.27 0.45 1.35
m 0.66 1.17 0.64 1.12 0.84 1.11 0.84 1.16 1.33 1.09 1.18 0.95 0.57 1.13 0.70 1.31 1.14 1.09 1.17 1.02 0.85 1.12 0.76 1.20
SD 0.32 0.14 0.19 0.13 0.27 0.14 0.35 0.14 0.67 0.13 0.81 0.17 0.25 0.18 0.30 0.23 0.71 0.15 0.62 0.15 0.55 0.14 0.33 0.18
p 0.88 0.88 0.046† 0.027† 0.15 0.51 0.61 0.02† 0.79 0.72 0.45 0.30 0.55 0.90 0.90 0.82

Threshold for statistical significance using Kruskal-Wallis test was set at P<0.05. Left, left-ear stimulation; Right, right-ear stimulation; Healthy, healthy-ear stimulation; Affected, affected-ear stimulation; Initial, initial MEG exam; 1 m, 1 month after initial exam (fixed stage); I/Ca, ipsilateral/contralateral ratio of N100m dipole moment amplitude in different hemispheres to monaural stimulation; I/Cl, ipsilateral/contralateral ratio of N100m dipole moment latency in different hemispheres to monaural stimulation; I/Cas, ipsilateral/contralateral ratio of N100m dipole moment amplitude in same hemisphere to stimulus at two ears; I/Cls, ipsilateral/contralateral ratio of N100m dipole moment latency in same hemisphere to stimulus at two ears; m, mean; sd, standard deviation; P, significance of difference in I/C among prognostic subgroups (i.e., complete, partial, and no recovery); †, significant difference.